Merck Group in the news

The stock market gained, led by strong pharma stocks, while defense stocks declined and oil prices fell due to increased supply.

Merck KGaA opens a new semiconductor hub in Wisconsin, as part of a $200 million US investment, and is considered 9% undervalued by analysts despite some market risks.

Merck KGaA is showing strong stock performance, while Drillisch faces potential market consolidation, and Wienerberger adjusts its financial outlook downwards amid challenging market conditions.

Merck KGaA, Bayer, and SAP are top DAX movers, while Bayer adjusts its strategy after a new investment, and several companies are being watched for their value-momentum potential.

Merck reported positive Phase 2b trial results for tulisokibart and stronger-than-expected second-quarter revenue, with an upcoming earnings call on October 29.

Merck's stock saw a strong recovery from its August 2025 low, faced resistance near 147.70 EUR, and is now attempting to resume its uptrend after a retracement.

Merck and The Hashgraph Group, with PwC Germany, launched a pilot program using combined digital and physical authentication technologies to ensure deforestation-free cocoa supply chains and meet new EUDR compliance.

EMD Electronics opened a 38,000 sq. ft. semiconductor R&D hub in Sheboygan Falls, Wisconsin, as part of a $200 million U.S. expansion to innovate advanced materials for chip manufacturing.

Merck KGaA Sponsored ADR offers financial documents and filings to provide insight into company performance and strategy for investment decisions.

Tom Sayer has been appointed as the new Global Head of Talent Acquisition for Merck, bringing over 20 years of experience in recruitment and talent acquisition from Accenture.

This article discusses the daily stock performance of several DAX companies, including Merck KGaA, Siemens Healthineers, Fresenius Medical Care, Siemens Energy, Deutsche Telekom, and Rheinmetall, on September 28th.

Merck's stock received a 'Hold' rating from two experts in September 2026, with an average price target of 147.00 EUR.

Two experts recommend holding Merck stock with an average price target of EUR 147.00, suggesting an 8.90 EUR increase from its current XETRA price of EUR 138.10.

Nicole Fella has been appointed Global HR Business Partner – Advanced Solutions at MilliporeSigma, bringing extensive international HR experience from previous roles at PUMA Group and cybex GmbH.

The document provides a financial metric, Return on Assets, for Merck KGaA, with a copyright from the American Bankers Association.

Merck KGaA is a key player in the growing photoactive materials market, which supports its strategic shift towards high-value science but doesn't immediately mitigate existing risks in other divisions.

Bio-Techne shareholders approved the company's acquisition by Merck KGaA but rejected the associated executive pay package.

Merck's investigational antibody Remigromig met its primary endpoint in a study for diabetic macular edema, showing non-inferiority to Ranibizumab but with some safety concerns.

Merck KGaA's acquisition of Bio-Techne received shareholder approval, furthering its expansion in the life sciences sector.

Bio-Techne shareholders approved the company's acquisition by Merck KGaA, moving the deal closer to completion.